Immune checkpoint inhibitors vs any first‐line chemotherapy
Adverse events grade 3 to 5 Range of · participants with advanced or metastatic muscle invasive bladder cancer
Immune checkpoint inhibitors probably leads to lower adverse events grade 3 to 5 Range of compared with any first‐line chemotherapy (moderate certainty).
1 finding from 1 review
- Immunotherapy for advanced or metastatic urothelial carcinoma 2023 · Cochrane Headline outcomes onlyRR 0.47 [0.29, 0.75]3 studies · 2046 participantsModerate